Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

IRA H THORLA

Allopathic & Osteopathic Physicians Dermatology

NPI
1730178047
CMS profile
305809
Location
BATON ROUGE, LA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2019 · Entire year

$3,127.81

181 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2019 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $3,127.81 181

By paying entity

PY2019 · entire year · sorted by reported total

Page 4 of 4; records 151–181 of 181 matching records. This page contains 31 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

IRA H THORLA

NPI 1730178047 · CMS profile ID 305809

Allopathic & Osteopathic Physicians / Dermatology

BATON ROUGE, LA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 4 of 4; records 151–181 of 181 matching records. This page contains 31 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1730178047?year=2019&recipient=provider&page=4#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
IRA H THORLA, NPI 1730178047, CMS profile ID 305809. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 4 of 4; records 151–181 of 181 matching records. This page contains 31 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1730178047?year=2019&recipient=provider&page=4#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
APA 7
IndustryPayments. (2026). IRA H THORLA, NPI 1730178047, CMS profile ID 305809. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 4 of 4; records 151–181 of 181 matching records. This page contains 31 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1730178047?year=2019&recipient=provider&page=4#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
Bluebook
IRA H THORLA, NPI 1730178047, CMS profile ID 305809, IndustryPayments, General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 4 of 4; records 151–181 of 181 matching records. This page contains 31 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e. https://industrypayments.org/provider/npi-1730178047?year=2019&recipient=provider&page=4#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2019

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2019 · Physicians and non-physician practitioners · CMS publication 2026-06-30

181 matching records · $3,127.81 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 181 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 151–181 of 181.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Promius Pharma LLC $28.9903/01/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 701096609 CMS
Mayne Pharma Inc. $17.8602/28/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 705526061 CMS
AbbVie, Inc. $20.4502/27/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 647855993 CMS
Janssen Biotech, Inc. $22.3002/26/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658752427 CMS
Galderma Laboratories, L.P. $13.3802/23/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 687722909 CMS
Celgene Corporation $16.1002/20/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 672752519 CMS
Novartis Pharmaceuticals Corporation $24.4202/19/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 660040339 CMS
LEO Pharma Inc. $12.4902/15/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 687274139 CMS
Mylan Pharmaceuticals Inc. $15.8002/14/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 694776791 CMS
Genentech USA, Inc. $16.4702/13/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 681289741 CMS
Sun Pharmaceutical Industries Inc. $24.9702/12/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 704601513 CMS
Lilly USA, LLC $21.0202/09/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 657859737 CMS
UCB, Inc. $27.6402/09/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 688252841 CMS
Lilly USA, LLC $17.7002/07/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 657853017 CMS
PFIZER INC. $9.9402/06/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 673239085 CMS
Regeneron Healthcare Solutions, Inc. $21.6202/06/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 673489129 CMS
Novartis Pharmaceuticals Corporation $21.3901/31/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 660040351 CMS
AbbVie, Inc. $23.5701/30/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 647855991 CMS
Medimetriks Pharmaceuticals, Inc. $34.7601/29/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 702111389 CMS
Galderma Laboratories, L.P. $13.7501/25/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 687722907 CMS
Novartis Pharmaceuticals Corporation $8.4201/25/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 660040387 CMS
Celgene Corporation $23.0601/23/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 672718519 CMS
Janssen Biotech, Inc. $18.1001/17/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658752421 CMS
GENZYME CORPORATION $22.2701/14/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 694270015 CMS
AbbVie, Inc. $19.9601/11/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 647855987 CMS
Genentech USA, Inc. $12.6501/09/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 681194257 CMS
Sun Pharmaceutical Industries Inc. $20.5701/08/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 704601511 CMS
Lilly USA, LLC $16.6801/07/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 657863241 CMS
Ortho Dermatologics, a division of Bausch Health US, LLC $15.3801/07/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 684606707 CMS
Novartis Pharmaceuticals Corporation $8.3201/02/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 660040337 CMS
Ortho Dermatologics, a division of Bausch Health US, LLC $16.0001/02/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 684606705 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $3,127.81 181
PY2020 $1,867.26 106
PY2021 $2,746.26 155
PY2022 $6,123.62 174
PY2023 $3,316.62 181
PY2024 $9,599.72 189
PY2025 $4,137.45 171

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $761,658.08 340
PY2024 Recipient $1,797.31 10
PY2024 Principal investigator $1,240,202.49 637
PY2023 Principal investigator $1,174,122.40 468
PY2022 Principal investigator $592,136.74 161
PY2021 Principal investigator $708,330.52 115
PY2020 Recipient $5,063.81 3
PY2020 Principal investigator $744,803.00 129
PY2019 Recipient $34,733.59 3
PY2019 Principal investigator $386,356.24 57

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

340 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 ABBVIE INC. $10,083.36 12/31/2025 Non-covered Recipient Entity
DELRICHT RESEARCH AT TOURO MEDICAL CENTER
BOTOX (onabotulinumtoxinA) for the Reduction of Masseter Muscle Prominence: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study No dispute reported 06/30/2026 1202534765
Principal investigator 1 PFIZER INC. $4,596.10 12/31/2025 Non-covered Recipient Entity
DelRicht LLC
A PHASE 3 RANDOMIZED DOUBLEBLIND 52WEEK PLACEBOCONTROLLED MULTICENTER STUDY INVESTIGATING THE EFFICACY SAFETY AND TOLERABILITY OF RITLECITINIB IN ADULT AND ADOLESCENT PARTICIPANTS WITH NON SEGMENTAL VITILIGO No dispute reported 06/30/2026 1228737623
Principal investigator 1 Biofrontera Inc. $300.00 12/22/2025 Non-covered Recipient Entity
DELRICHT RESEARCH
STUDY TO EVALUATE THE SAFETY, TOLERABILITY AND EFFICACY OF BF-200 ALA (AMELUZ) IN THE FIELD-DIRECTED TREATMENT OF ACTINIC KERATOSIS (AK) ON THE EXTREMITIES AND NECK/TRUNK WITH PHOTODYNAMIC THERAPY (PDT) USING A RHODOLED LAMP No dispute reported 06/30/2026 1208907803
Principal investigator 1 Biofrontera Inc. $300.00 12/22/2025 Non-covered Recipient Entity
DELRICHT RESEARCH
STUDY TO EVALUATE THE SAFETY AND EFFICACY OFBF-200ALA(AMELUZ) AND BF-RHODOLED IN THE TREATMENT OF MODERATE TO SEVERE ACNE VULGARIS WITH PHOTODYNAMIC THERAPY IN ADULTS No dispute reported 06/30/2026 1208907807
Principal investigator 1 SANOFI PASTEUR INC. $3,400.41 12/22/2025 Non-covered Recipient Entity
Delricht Llc
A Phase I/II, Randomized, Placebo-controlled, Multi-arm, Dose-finding Study to Evaluate the Safety, Efficacy and Immunogenicity of an Acne mRNA Vaccine Candidate in Adults With Moderate to Severe Acne 18 to 45 Years of Age No dispute reported 06/30/2026 1226112748
Principal investigator 1 SANOFI US SERVICES INC. $16,000.00 12/22/2025 Non-covered Recipient Entity
Delricht LLC
A Randomized, Double-blind, Placebo-controlled, Dose-ranging Phase 2 Study of Brivekimig Followed by a Maintenance Period in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1226128492
Principal investigator 1 Incyte Corporation $293.00 12/19/2025 Non-covered Recipient Entity
DELRICHT RESEARCH
Rollover Study for Participants Previously Enrolled in Clinical Trials of Povorcitinib No dispute reported 06/30/2026 1240523853
Principal investigator 1 Incyte Corporation $259.00 12/19/2025 Non-covered Recipient Entity
DELRICHT RESEARCH
Rollover Study for Participants Previously Enrolled in Clinical Trials of Povorcitinib No dispute reported 06/30/2026 1240523857
Principal investigator 1 Incyte Corporation $1,385.00 12/19/2025 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240523872
Principal investigator 1 ABBVIE INC. $2,000.00 12/17/2025 Non-covered Recipient Entity
DELRICHT LLC
BOTOX (onabotulinumtoxinA) for the Reduction of Masseter Muscle Prominence A Phase 3 Multicenter Randomized Double-Blind Placebo-Controlled Study No dispute reported 06/30/2026 1202531006
Principal investigator 1 Incyte Corporation $10,000.00 12/17/2025 Non-covered Recipient Entity
DELRICHT RESEARCH
A Maximal Use Trial of Ruxolitinib Cream in Adult and Adolescent Participants With Hidradenitis Suppurativa No dispute reported 06/30/2026 1240523930
Principal investigator 1 Incyte Corporation $2,077.00 12/17/2025 Non-covered Recipient Entity
DELRICHT RESEARCH
A Maximal Use Trial of Ruxolitinib Cream in Adult and Adolescent Participants With Hidradenitis Suppurativa No dispute reported 06/30/2026 1240523943
Principal investigator 1 Incyte Corporation $1,500.00 12/17/2025 Non-covered Recipient Entity
DELRICHT RESEARCH
A Maximal Use Trial of Ruxolitinib Cream in Adult and Adolescent Participants With Hidradenitis Suppurativa No dispute reported 06/30/2026 1240524010
Principal investigator 1 Incyte Corporation $793.00 12/17/2025 Non-covered Recipient Entity
DELRICHT RESEARCH
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240524047
Principal investigator 1 Incyte Corporation $1,979.00 12/17/2025 Non-covered Recipient Entity
DELRICHT RESEARCH
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240524062
Principal investigator 1 Incyte Corporation $50.00 12/17/2025 Non-covered Recipient Entity
DELRICHT RESEARCH
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240524142
Principal investigator 1 Incyte Corporation $5,000.00 12/17/2025 Non-covered Recipient Entity
DELRICHT RESEARCH
A Maximal Use Trial of Ruxolitinib Cream in Adult and Adolescent Participants With Hidradenitis Suppurativa No dispute reported 06/30/2026 1240524152
Principal investigator 1 Incyte Corporation $2,500.00 12/17/2025 Non-covered Recipient Entity
DELRICHT RESEARCH
A Maximal Use Trial of Ruxolitinib Cream in Adult and Adolescent Participants With Hidradenitis Suppurativa No dispute reported 06/30/2026 1240524176
Principal investigator 1 SANOFI PASTEUR INC. $500.00 12/16/2025 Non-covered Recipient Entity
Delricht Llc
A Phase I/II, Randomized, Placebo-controlled, Multi-arm, Dose-finding Study to Evaluate the Safety, Efficacy and Immunogenicity of an Acne mRNA Vaccine Candidate in Adults With Moderate to Severe Acne 18 to 45 Years of Age No dispute reported 06/30/2026 1226112476
Principal investigator 1 SANOFI PASTEUR INC. $500.00 12/16/2025 Non-covered Recipient Entity
Delricht Llc
A Phase I/II, Randomized, Placebo-controlled, Multi-arm, Dose-finding Study to Evaluate the Safety, Efficacy and Immunogenicity of an Acne mRNA Vaccine Candidate in Adults With Moderate to Severe Acne 18 to 45 Years of Age No dispute reported 06/30/2026 1226112721
Principal investigator 1 Incyte Corporation $380.00 12/11/2025 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240523875
Principal investigator 1 Incyte Corporation $500.00 12/10/2025 Non-covered Recipient Entity
DELRICHT RESEARCH
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240523883
Principal investigator 1 Incyte Corporation $259.00 12/04/2025 Non-covered Recipient Entity
DELRICHT RESEARCH
Rollover Study for Participants Previously Enrolled in Clinical Trials of Povorcitinib No dispute reported 06/30/2026 1240523863
Principal investigator 1 Incyte Corporation $293.00 12/04/2025 Non-covered Recipient Entity
DELRICHT RESEARCH
Rollover Study for Participants Previously Enrolled in Clinical Trials of Povorcitinib No dispute reported 06/30/2026 1240523867
Principal investigator 1 Incyte Corporation $1,604.00 12/04/2025 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240523879
Principal investigator 1 Incyte Corporation $16.59 12/01/2025 Non-covered Recipient Entity
DELRICHT RESEARCH
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240523894
Principal investigator 1 Incyte Corporation $70.00 12/01/2025 Non-covered Recipient Entity
DELRICHT RESEARCH
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240523898
Principal investigator 1 Incyte Corporation $49.36 12/01/2025 Non-covered Recipient Entity
DELRICHT RESEARCH
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240523906
Principal investigator 1 Incyte Corporation $48.54 12/01/2025 Non-covered Recipient Entity
DELRICHT RESEARCH
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240523910
Principal investigator 1 Incyte Corporation $52.14 12/01/2025 Non-covered Recipient Entity
DELRICHT RESEARCH
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240523938
Principal investigator 1 Incyte Corporation $264.00 12/01/2025 Non-covered Recipient Entity
DELRICHT RESEARCH
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240523974
Principal investigator 1 Incyte Corporation $14.22 12/01/2025 Non-covered Recipient Entity
DELRICHT RESEARCH
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240523978
Principal investigator 1 Incyte Corporation $53.20 12/01/2025 Non-covered Recipient Entity
DELRICHT RESEARCH
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240523998
Principal investigator 1 Incyte Corporation $1.02 12/01/2025 Non-covered Recipient Entity
DELRICHT RESEARCH
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240524124
Principal investigator 1 Incyte Corporation $1,533.00 12/01/2025 Non-covered Recipient Entity
DELRICHT RESEARCH
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240524168
Principal investigator 1 Incyte Corporation $18.96 12/01/2025 Non-covered Recipient Entity
DELRICHT RESEARCH
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240524180
Principal investigator 1 Incyte Corporation $7.11 12/01/2025 Non-covered Recipient Entity
DELRICHT RESEARCH
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240524200
Principal investigator 1 Incyte Corporation $68.70 12/01/2025 Non-covered Recipient Entity
DELRICHT RESEARCH
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240524230
Principal investigator 1 SANOFI PASTEUR INC. $1,007.00 12/01/2025 Non-covered Recipient Entity
Delricht Llc
A Phase I/II, Randomized, Placebo-controlled, Multi-arm, Dose-finding Study to Evaluate the Safety, Efficacy and Immunogenicity of an Acne mRNA Vaccine Candidate in Adults With Moderate to Severe Acne 18 to 45 Years of Age No dispute reported 06/30/2026 1226112446
Principal investigator 1 Biofrontera Inc. $300.00 11/28/2025 Non-covered Recipient Entity
DELRICHT RESEARCH
STUDY TO EVALUATE THE SAFETY AND EFFICACY OFBF-200ALA(AMELUZ) AND BF-RHODOLED IN THE TREATMENT OF MODERATE TO SEVERE ACNE VULGARIS WITH PHOTODYNAMIC THERAPY IN ADULTS No dispute reported 06/30/2026 1208907780
Principal investigator 1 Biofrontera Inc. $300.00 11/28/2025 Non-covered Recipient Entity
DELRICHT RESEARCH
STUDY TO EVALUATE THE SAFETY, TOLERABILITY AND EFFICACY OF BF-200 ALA (AMELUZ) IN THE FIELD-DIRECTED TREATMENT OF ACTINIC KERATOSIS (AK) ON THE EXTREMITIES AND NECK/TRUNK WITH PHOTODYNAMIC THERAPY (PDT) USING A RHODOLED LAMP No dispute reported 06/30/2026 1208907783
Principal investigator 1 Biofrontera Inc. $100.00 11/27/2025 Non-covered Recipient Entity
DELRICHT RESEARCH
STUDY TO EVALUATE THE SAFETY, TOLERABILITY AND EFFICACY OF BF-200 ALA (AMELUZ) IN THE FIELD-DIRECTED TREATMENT OF ACTINIC KERATOSIS (AK) ON THE EXTREMITIES AND NECK/TRUNK WITH PHOTODYNAMIC THERAPY (PDT) USING A RHODOLED LAMP No dispute reported 06/30/2026 1208907736
Principal investigator 1 Biofrontera Inc. $50.00 11/27/2025 Non-covered Recipient Entity
DELRICHT RESEARCH
STUDY TO EVALUATE THE SAFETY, TOLERABILITY AND EFFICACY OF BF-200 ALA (AMELUZ) IN THE FIELD-DIRECTED TREATMENT OF ACTINIC KERATOSIS (AK) ON THE EXTREMITIES AND NECK/TRUNK WITH PHOTODYNAMIC THERAPY (PDT) USING A RHODOLED LAMP No dispute reported 06/30/2026 1208907741
Principal investigator 1 Biofrontera Inc. $300.00 11/27/2025 Non-covered Recipient Entity
DELRICHT RESEARCH
STUDY TO EVALUATE THE SAFETY AND EFFICACY OFBF-200ALA(AMELUZ) AND BF-RHODOLED IN THE TREATMENT OF MODERATE TO SEVERE ACNE VULGARIS WITH PHOTODYNAMIC THERAPY IN ADULTS No dispute reported 06/30/2026 1208907746
Principal investigator 1 Biofrontera Inc. $300.00 11/27/2025 Non-covered Recipient Entity
DELRICHT RESEARCH
STUDY TO EVALUATE THE SAFETY AND EFFICACY OFBF-200ALA(AMELUZ) AND BF-RHODOLED IN THE TREATMENT OF MODERATE TO SEVERE ACNE VULGARIS WITH PHOTODYNAMIC THERAPY IN ADULTS No dispute reported 06/30/2026 1208907750
Principal investigator 1 Incyte Corporation $100.00 11/25/2025 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240523830
Principal investigator 1 Incyte Corporation $380.00 11/25/2025 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240523839
Principal investigator 1 Incyte Corporation $6,600.00 11/25/2025 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240523848
Principal investigator 1 Incyte Corporation $1,736.00 11/24/2025 Non-covered Recipient Entity
DELRICHT RESEARCH
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240524002
Principal investigator 1 Incyte Corporation $70.00 11/21/2025 Non-covered Recipient Entity
DELRICHT RESEARCH
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240523890
Principal investigator 1 Incyte Corporation $446.00 11/21/2025 Non-covered Recipient Entity
DELRICHT RESEARCH
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240523926
Principal investigator 1 Incyte Corporation $2,044.00 11/21/2025 Non-covered Recipient Entity
DELRICHT RESEARCH
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240523985
Principal investigator 1 Incyte Corporation $133.00 11/21/2025 Non-covered Recipient Entity
DELRICHT RESEARCH
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240523993
Principal investigator 1 Incyte Corporation $183.55 11/21/2025 Non-covered Recipient Entity
DELRICHT RESEARCH
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240524055
Principal investigator 1 Incyte Corporation $616.00 11/21/2025 Non-covered Recipient Entity
DELRICHT RESEARCH
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240524093
Principal investigator 1 Incyte Corporation $194.18 11/21/2025 Non-covered Recipient Entity
DELRICHT RESEARCH
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240524115
Principal investigator 1 Incyte Corporation $26.60 11/21/2025 Non-covered Recipient Entity
DELRICHT RESEARCH
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240524128
Principal investigator 1 Incyte Corporation $140.00 11/21/2025 Non-covered Recipient Entity
DELRICHT RESEARCH
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240524132
Principal investigator 1 Incyte Corporation $88.00 11/21/2025 Non-covered Recipient Entity
DELRICHT RESEARCH
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240524137
Principal investigator 1 Incyte Corporation $511.00 11/21/2025 Non-covered Recipient Entity
DELRICHT RESEARCH
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240524144
Principal investigator 1 Incyte Corporation $1,632.00 11/21/2025 Non-covered Recipient Entity
DELRICHT RESEARCH
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240524148
Principal investigator 1 Incyte Corporation $266.00 11/21/2025 Non-covered Recipient Entity
DELRICHT RESEARCH
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240524195
Principal investigator 1 Incyte Corporation $1,979.00 11/19/2025 Non-covered Recipient Entity
DELRICHT RESEARCH
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240523934
Principal investigator 1 Incyte Corporation $50.00 11/19/2025 Non-covered Recipient Entity
DELRICHT RESEARCH
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240524006
Principal investigator 1 Incyte Corporation $50.00 11/19/2025 Non-covered Recipient Entity
DELRICHT RESEARCH
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240524018
Principal investigator 1 Incyte Corporation $50.00 11/19/2025 Non-covered Recipient Entity
DELRICHT RESEARCH
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240524030
Principal investigator 1 Incyte Corporation $159.00 11/19/2025 Non-covered Recipient Entity
DELRICHT RESEARCH
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240524103
Principal investigator 1 Incyte Corporation $159.00 11/19/2025 Non-covered Recipient Entity
DELRICHT RESEARCH
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240524108
Principal investigator 1 Incyte Corporation $159.00 11/19/2025 Non-covered Recipient Entity
DELRICHT RESEARCH
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240524111
Principal investigator 1 Incyte Corporation $2,065.00 11/19/2025 Non-covered Recipient Entity
DELRICHT RESEARCH
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240524120
Principal investigator 1 Incyte Corporation $2,252.00 11/19/2025 Non-covered Recipient Entity
DELRICHT RESEARCH
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240524158
Principal investigator 1 Incyte Corporation $2,252.00 11/19/2025 Non-covered Recipient Entity
DELRICHT RESEARCH
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240524164
Principal investigator 1 Incyte Corporation $43.00 11/19/2025 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240524172
Principal investigator 1 Incyte Corporation $3,280.00 11/19/2025 Non-covered Recipient Entity
DELRICHT RESEARCH
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240524183
Principal investigator 1 Incyte Corporation $3,280.00 11/19/2025 Non-covered Recipient Entity
DELRICHT RESEARCH
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240524187
Principal investigator 1 Incyte Corporation $3,280.00 11/19/2025 Non-covered Recipient Entity
DELRICHT RESEARCH
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240524191
Principal investigator 1 Incyte Corporation $2,112.00 11/19/2025 Non-covered Recipient Entity
DELRICHT RESEARCH
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240524204
Principal investigator 1 Incyte Corporation $2,112.00 11/19/2025 Non-covered Recipient Entity
DELRICHT RESEARCH
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240524209
Principal investigator 1 ABBVIE INC. $3,054.00 11/17/2025 Non-covered Recipient Entity
DELRICHT LLC
BOTOX (onabotulinumtoxinA) for the Reduction of Masseter Muscle Prominence A Phase 3 Multicenter Randomized Double-Blind Placebo-Controlled Study No dispute reported 06/30/2026 1202524453
Principal investigator 1 ABBVIE INC. $3,246.00 11/17/2025 Non-covered Recipient Entity
DELRICHT LLC
BOTOX (onabotulinumtoxinA) for the Reduction of Masseter Muscle Prominence A Phase 3 Multicenter Randomized Double-Blind Placebo-Controlled Study No dispute reported 06/30/2026 1202524459
Principal investigator 1 SANOFI PASTEUR INC. $7,772.54 11/14/2025 Non-covered Recipient Entity
Delricht Llc
A Phase I/II, Randomized, Placebo-controlled, Multi-arm, Dose-finding Study to Evaluate the Safety, Efficacy and Immunogenicity of an Acne mRNA Vaccine Candidate in Adults With Moderate to Severe Acne 18 to 45 Years of Age No dispute reported 06/30/2026 1226112836
Principal investigator 1 Incyte Corporation $43.00 11/12/2025 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240523886
Principal investigator 1 Incyte Corporation $300.00 11/12/2025 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240523918
Principal investigator 1 Incyte Corporation $300.00 11/12/2025 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240523922
Principal investigator 1 Incyte Corporation $30.00 11/12/2025 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240523981
Principal investigator 1 Incyte Corporation $1,597.00 11/10/2025 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240523914
Principal investigator 1 Incyte Corporation $100.00 11/07/2025 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240523834
Principal investigator 1 Incyte Corporation $2,464.00 11/07/2025 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240523844
Principal investigator 1 SANOFI PASTEUR INC. $33,007.81 10/31/2025 Non-covered Recipient Entity
Delricht Llc
A Phase I/II, Randomized, Placebo-controlled, Multi-arm, Dose-finding Study to Evaluate the Safety, Efficacy and Immunogenicity of an Acne mRNA Vaccine Candidate in Adults With Moderate to Severe Acne 18 to 45 Years of Age No dispute reported 06/30/2026 1226112512
Principal investigator 1 Incyte Corporation $380.00 10/29/2025 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240523809
Principal investigator 1 Biofrontera Inc. $84,601.22 10/24/2025 Non-covered Recipient Entity
DELRICHT RESEARCH
STUDY TO EVALUATE THE SAFETY, TOLERABILITY AND EFFICACY OF BF-200 ALA (AMELUZ) IN THE FIELD-DIRECTED TREATMENT OF ACTINIC KERATOSIS (AK) ON THE EXTREMITIES AND NECK/TRUNK WITH PHOTODYNAMIC THERAPY (PDT) USING A RHODOLED LAMP No dispute reported 06/30/2026 1208907681
Principal investigator 1 Biofrontera Inc. $717.23 10/24/2025 Non-covered Recipient Entity
DELRICHT RESEARCH
STUDY TO EVALUATE THE SAFETY, TOLERABILITY AND EFFICACY OF BF-200 ALA (AMELUZ) IN THE FIELD-DIRECTED TREATMENT OF ACTINIC KERATOSIS (AK) ON THE EXTREMITIES AND NECK/TRUNK WITH PHOTODYNAMIC THERAPY (PDT) USING A RHODOLED LAMP No dispute reported 06/30/2026 1208907685
Principal investigator 1 Biofrontera Inc. $300.00 10/24/2025 Non-covered Recipient Entity
DELRICHT RESEARCH
STUDY TO EVALUATE THE SAFETY, TOLERABILITY AND EFFICACY OF BF-200 ALA (AMELUZ) IN THE FIELD-DIRECTED TREATMENT OF ACTINIC KERATOSIS (AK) ON THE EXTREMITIES AND NECK/TRUNK WITH PHOTODYNAMIC THERAPY (PDT) USING A RHODOLED LAMP No dispute reported 06/30/2026 1208907689
Principal investigator 1 Biofrontera Inc. $300.00 10/24/2025 Non-covered Recipient Entity
DELRICHT RESEARCH
STUDY TO EVALUATE THE SAFETY AND EFFICACY OFBF-200ALA(AMELUZ) AND BF-RHODOLED IN THE TREATMENT OF MODERATE TO SEVERE ACNE VULGARIS WITH PHOTODYNAMIC THERAPY IN ADULTS No dispute reported 06/30/2026 1208907694
Principal investigator 1 Incyte Corporation $1,483.00 10/23/2025 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240523818
Principal investigator 1 Incyte Corporation $1,599.00 10/20/2025 Non-covered Recipient Entity
DELRICHT RESEARCH
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240524021
Principal investigator 1 Incyte Corporation $1,599.00 10/20/2025 Non-covered Recipient Entity
DELRICHT RESEARCH
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240524026
Principal investigator 1 Incyte Corporation $1,483.00 10/16/2025 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240523813
Principal investigator 1 ABBVIE INC. $600.00 10/15/2025 Non-covered Recipient Entity
DELRICHT LLC
BOTOX (onabotulinumtoxinA) for the Reduction of Masseter Muscle Prominence A Phase 3 Multicenter Randomized Double-Blind Placebo-Controlled Study No dispute reported 06/30/2026 1202516989
Principal investigator 1 ABBVIE INC. $250.00 10/15/2025 Non-covered Recipient Entity
DELRICHT LLC
BOTOX (onabotulinumtoxinA) for the Reduction of Masseter Muscle Prominence A Phase 3 Multicenter Randomized Double-Blind Placebo-Controlled Study No dispute reported 06/30/2026 1202516991
Principal investigator 1 ABBVIE INC. $1,500.00 10/15/2025 Non-covered Recipient Entity
DELRICHT LLC
BOTOX (onabotulinumtoxinA) for the Reduction of Masseter Muscle Prominence A Phase 3 Multicenter Randomized Double-Blind Placebo-Controlled Study No dispute reported 06/30/2026 1202516993
Principal investigator 1 Incyte Corporation $86.00 10/15/2025 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240523947
Principal investigator 1 Incyte Corporation $40.00 10/15/2025 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240523989
Principal investigator 1 SANOFI PASTEUR INC. $500.00 10/13/2025 Non-covered Recipient Entity
Delricht Llc
A Phase I/II, Randomized, Placebo-controlled, Multi-arm, Dose-finding Study to Evaluate the Safety, Efficacy and Immunogenicity of an Acne mRNA Vaccine Candidate in Adults With Moderate to Severe Acne 18 to 45 Years of Age No dispute reported 06/30/2026 1226112818
Principal investigator 1 Incyte Corporation $293.00 10/09/2025 Non-covered Recipient Entity
DELRICHT RESEARCH
Rollover Study for Participants Previously Enrolled in Clinical Trials of Povorcitinib No dispute reported 06/30/2026 1240523802
Principal investigator 1 Incyte Corporation $3,000.00 10/09/2025 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240523805
Principal investigator 1 Incyte Corporation $259.00 10/09/2025 Non-covered Recipient Entity
DELRICHT RESEARCH
Rollover Study for Participants Previously Enrolled in Clinical Trials of Povorcitinib No dispute reported 06/30/2026 1240523826
Principal investigator 1 Incyte Corporation $1,979.00 10/09/2025 Non-covered Recipient Entity
DELRICHT RESEARCH
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240523952
Principal investigator 1 Incyte Corporation $1,979.00 10/09/2025 Non-covered Recipient Entity
DELRICHT RESEARCH
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240523956
Principal investigator 1 Incyte Corporation $159.00 10/09/2025 Non-covered Recipient Entity
DELRICHT RESEARCH
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240523959
Principal investigator 1 Incyte Corporation $159.00 10/09/2025 Non-covered Recipient Entity
DELRICHT RESEARCH
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240523963
Principal investigator 1 Incyte Corporation $159.00 10/09/2025 Non-covered Recipient Entity
DELRICHT RESEARCH
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240523967
Principal investigator 1 Incyte Corporation $159.00 10/09/2025 Non-covered Recipient Entity
DELRICHT RESEARCH
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240523970
Principal investigator 1 Incyte Corporation $2,252.00 10/09/2025 Non-covered Recipient Entity
DELRICHT RESEARCH
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240524034
Principal investigator 1 Incyte Corporation $2,252.00 10/09/2025 Non-covered Recipient Entity
DELRICHT RESEARCH
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240524038
Principal investigator 1 Incyte Corporation $2,252.00 10/09/2025 Non-covered Recipient Entity
DELRICHT RESEARCH
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240524042
Principal investigator 1 Incyte Corporation $50.00 10/09/2025 Non-covered Recipient Entity
DELRICHT RESEARCH
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240524074
Principal investigator 1 Incyte Corporation $50.00 10/09/2025 Non-covered Recipient Entity
DELRICHT RESEARCH
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240524078
Principal investigator 1 Incyte Corporation $50.00 10/09/2025 Non-covered Recipient Entity
DELRICHT RESEARCH
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240524082
Principal investigator 1 Incyte Corporation $50.00 10/09/2025 Non-covered Recipient Entity
DELRICHT RESEARCH
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240524085
Principal investigator 1 Incyte Corporation $50.00 10/09/2025 Non-covered Recipient Entity
DELRICHT RESEARCH
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240524089
Principal investigator 1 Incyte Corporation $2,112.00 10/09/2025 Non-covered Recipient Entity
DELRICHT RESEARCH
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240524096
Principal investigator 1 Incyte Corporation $2,112.00 10/09/2025 Non-covered Recipient Entity
DELRICHT RESEARCH
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240524100
Principal investigator 1 Incyte Corporation $3,280.00 10/09/2025 Non-covered Recipient Entity
DELRICHT RESEARCH
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240524214
Principal investigator 1 Incyte Corporation $3,280.00 10/09/2025 Non-covered Recipient Entity
DELRICHT RESEARCH
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240524217
Principal investigator 1 Incyte Corporation $3,280.00 10/09/2025 Non-covered Recipient Entity
DELRICHT RESEARCH
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240524221
Principal investigator 1 Incyte Corporation $3,280.00 10/09/2025 Non-covered Recipient Entity
DELRICHT RESEARCH
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240524226
Principal investigator 1 Biofrontera Inc. $300.00 10/08/2025 Non-covered Recipient Entity
DELRICHT RESEARCH
STUDY TO EVALUATE THE SAFETY AND EFFICACY OFBF-200ALA(AMELUZ) AND BF-RHODOLED IN THE TREATMENT OF MODERATE TO SEVERE ACNE VULGARIS WITH PHOTODYNAMIC THERAPY IN ADULTS No dispute reported 06/30/2026 1208907663
Principal investigator 1 Biofrontera Inc. $300.00 10/08/2025 Non-covered Recipient Entity
DELRICHT RESEARCH
STUDY TO EVALUATE THE SAFETY, TOLERABILITY AND EFFICACY OF BF-200 ALA (AMELUZ) IN THE FIELD-DIRECTED TREATMENT OF ACTINIC KERATOSIS (AK) ON THE EXTREMITIES AND NECK/TRUNK WITH PHOTODYNAMIC THERAPY (PDT) USING A RHODOLED LAMP No dispute reported 06/30/2026 1208907667
Principal investigator 1 Biofrontera Inc. $85.00 10/08/2025 Non-covered Recipient Entity
DELRICHT RESEARCH
STUDY TO EVALUATE THE SAFETY, TOLERABILITY AND EFFICACY OF BF-200 ALA (AMELUZ) IN THE FIELD-DIRECTED TREATMENT OF ACTINIC KERATOSIS (AK) ON THE EXTREMITIES AND NECK/TRUNK WITH PHOTODYNAMIC THERAPY (PDT) USING A RHODOLED LAMP No dispute reported 06/30/2026 1208907671
Principal investigator 1 Incyte Corporation $2,200.00 10/08/2025 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240524155
Principal investigator 1 Incyte Corporation $1,385.00 10/03/2025 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240523822
Principal investigator 1 Incyte Corporation $43.00 10/02/2025 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240523902
Principal investigator 1 Incyte Corporation $2,377.00 10/02/2025 Non-covered Recipient Entity
DELRICHT RESEARCH
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240524014
Principal investigator 1 Incyte Corporation $300.00 10/02/2025 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240524051
Principal investigator 1 Incyte Corporation $30.00 10/02/2025 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240524065
Principal investigator 1 Incyte Corporation $1,736.00 10/02/2025 Non-covered Recipient Entity
DELRICHT RESEARCH
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240524070
Principal investigator 1 SANOFI PASTEUR INC. $300.00 10/02/2025 Non-covered Recipient Entity
Delricht Llc
A Phase I/II, Randomized, Placebo-controlled, Multi-arm, Dose-finding Study to Evaluate the Safety, Efficacy and Immunogenicity of an Acne mRNA Vaccine Candidate in Adults With Moderate to Severe Acne 18 to 45 Years of Age No dispute reported 06/30/2026 1226112756
Principal investigator 1 Incyte Corporation $1,385.00 09/23/2025 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240523709
Principal investigator 1 Incyte Corporation $2,868.00 09/18/2025 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240523706
Principal investigator 1 Incyte Corporation $1,979.00 09/12/2025 Non-covered Recipient Entity
DELRICHT RESEARCH
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240523717
Principal investigator 1 Incyte Corporation $159.00 09/12/2025 Non-covered Recipient Entity
DELRICHT RESEARCH
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240523722
Principal investigator 1 Incyte Corporation $50.00 09/12/2025 Non-covered Recipient Entity
DELRICHT RESEARCH
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240523730
Principal investigator 1 Incyte Corporation $3,280.00 09/12/2025 Non-covered Recipient Entity
DELRICHT RESEARCH
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240523734
Principal investigator 1 Incyte Corporation $2,252.00 09/12/2025 Non-covered Recipient Entity
DELRICHT RESEARCH
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240523739
Principal investigator 1 Incyte Corporation $50.00 09/12/2025 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240523771
Principal investigator 1 Incyte Corporation $3,280.00 09/12/2025 Non-covered Recipient Entity
DELRICHT RESEARCH
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240523790
Principal investigator 1 Incyte Corporation $2,200.00 09/10/2025 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240523748
Principal investigator 1 Incyte Corporation $200.00 09/04/2025 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240523713
Principal investigator 1 Incyte Corporation $552.00 08/26/2025 Non-covered Recipient Entity
DELRICHT RESEARCH
Rollover Study for Participants Previously Enrolled in Clinical Trials of Povorcitinib No dispute reported 06/30/2026 1240523682
Principal investigator 1 Incyte Corporation $1,604.00 08/26/2025 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240523693
Principal investigator 1 Incyte Corporation $100.00 08/26/2025 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240523697
Principal investigator 1 Biofrontera Inc. $300.00 08/22/2025 Non-covered Recipient Entity
DELRICHT RESEARCH
STUDY TO EVALUATE THE SAFETY AND EFFICACY OFBF-200ALA(AMELUZ) AND BF-RHODOLED IN THE TREATMENT OF MODERATE TO SEVERE ACNE VULGARIS WITH PHOTODYNAMIC THERAPY IN ADULTS No dispute reported 06/30/2026 1208907591
Principal investigator 1 Biofrontera Inc. $300.00 08/22/2025 Non-covered Recipient Entity
DELRICHT RESEARCH
STUDY TO EVALUATE THE SAFETY, TOLERABILITY AND EFFICACY OF BF-200 ALA (AMELUZ) IN THE FIELD-DIRECTED TREATMENT OF ACTINIC KERATOSIS (AK) ON THE EXTREMITIES AND NECK/TRUNK WITH PHOTODYNAMIC THERAPY (PDT) USING A RHODOLED LAMP No dispute reported 06/30/2026 1208907595
Principal investigator 1 Incyte Corporation $2,250.00 08/21/2025 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240523701
Principal investigator 1 Incyte Corporation $446.00 08/20/2025 Non-covered Recipient Entity
DELRICHT RESEARCH
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240523743
Principal investigator 1 ABBVIE INC. $5,021.94 08/14/2025 Non-covered Recipient Entity
DELRICHT LLC
BOTOX (onabotulinumtoxinA) for the Reduction of Masseter Muscle Prominence A Phase 3 Multicenter Randomized Double-Blind Placebo-Controlled Study No dispute reported 06/30/2026 1202504597
Principal investigator 1 ABBVIE INC. $123.00 08/14/2025 Non-covered Recipient Entity
DELRICHT LLC
BOTOX (onabotulinumtoxinA) for the Reduction of Masseter Muscle Prominence A Phase 3 Multicenter Randomized Double-Blind Placebo-Controlled Study No dispute reported 06/30/2026 1202504599
Principal investigator 1 Incyte Corporation $380.00 08/14/2025 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240523689
Principal investigator 1 Incyte Corporation $30.00 08/13/2025 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240523767
Principal investigator 1 Incyte Corporation $43.00 08/13/2025 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240523794
Principal investigator 1 Biofrontera Inc. $1,000.00 08/12/2025 Non-covered Recipient Entity
DELRICHT RESEARCH
STUDY TO EVALUATE THE SAFETY AND EFFICACY OFBF-200ALA(AMELUZ) AND BF-RHODOLED IN THE TREATMENT OF MODERATE TO SEVERE ACNE VULGARIS WITH PHOTODYNAMIC THERAPY IN ADULTS No dispute reported 06/30/2026 1208907558
Principal investigator 1 Biofrontera Inc. $300.00 08/12/2025 Non-covered Recipient Entity
DELRICHT RESEARCH
STUDY TO EVALUATE THE SAFETY, TOLERABILITY AND EFFICACY OF BF-200 ALA (AMELUZ) IN THE FIELD-DIRECTED TREATMENT OF ACTINIC KERATOSIS (AK) ON THE EXTREMITIES AND NECK/TRUNK WITH PHOTODYNAMIC THERAPY (PDT) USING A RHODOLED LAMP No dispute reported 06/30/2026 1208907561
Principal investigator 1 Biofrontera Inc. $300.00 08/12/2025 Non-covered Recipient Entity
DELRICHT RESEARCH
STUDY TO EVALUATE THE SAFETY AND EFFICACY OFBF-200ALA(AMELUZ) AND BF-RHODOLED IN THE TREATMENT OF MODERATE TO SEVERE ACNE VULGARIS WITH PHOTODYNAMIC THERAPY IN ADULTS No dispute reported 06/30/2026 1208907566
Principal investigator 1 Biofrontera Inc. $300.00 08/12/2025 Non-covered Recipient Entity
DELRICHT RESEARCH
STUDY TO EVALUATE THE SAFETY, TOLERABILITY AND EFFICACY OF BF-200 ALA (AMELUZ) IN THE FIELD-DIRECTED TREATMENT OF ACTINIC KERATOSIS (AK) ON THE EXTREMITIES AND NECK/TRUNK WITH PHOTODYNAMIC THERAPY (PDT) USING A RHODOLED LAMP No dispute reported 06/30/2026 1208907570
Principal investigator 1 Biofrontera Inc. $300.00 08/12/2025 Non-covered Recipient Entity
DELRICHT RESEARCH
STUDY TO EVALUATE THE SAFETY AND EFFICACY OFBF-200ALA(AMELUZ) AND BF-RHODOLED IN THE TREATMENT OF MODERATE TO SEVERE ACNE VULGARIS WITH PHOTODYNAMIC THERAPY IN ADULTS No dispute reported 06/30/2026 1208907574
Principal investigator 1 Incyte Corporation $6,080.00 08/07/2025 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240523686
Principal investigator 1 Incyte Corporation $2,000.00 08/07/2025 Non-covered Recipient Entity
DELRICHT RESEARCH
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240523725
Principal investigator 1 Incyte Corporation $10,000.00 08/07/2025 Non-covered Recipient Entity
DELRICHT RESEARCH
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240523780
Principal investigator 1 Incyte Corporation $300.00 08/06/2025 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240523745
Principal investigator 1 ABBVIE INC. $41.00 08/04/2025 Non-covered Recipient Entity
DELRICHT LLC
BOTOX (onabotulinumtoxinA) for the Reduction of Masseter Muscle Prominence A Phase 3 Multicenter Randomized Double-Blind Placebo-Controlled Study No dispute reported 06/30/2026 1202500940
Principal investigator 1 Incyte Corporation $1,553.00 08/04/2025 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240523776
Principal investigator 1 Incyte Corporation $300.00 08/01/2025 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240523759
Principal investigator 1 Incyte Corporation $50.00 07/28/2025 Non-covered Recipient Entity
DELRICHT RESEARCH
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240523785
Principal investigator 1 Incyte Corporation $1,519.00 07/22/2025 Non-covered Recipient Entity
DELRICHT RESEARCH
Rollover Study for Participants Previously Enrolled in Clinical Trials of Povorcitinib No dispute reported 06/30/2026 1240523657
Principal investigator 1 Incyte Corporation $2,524.00 07/18/2025 Non-covered Recipient Entity
DELRICHT RESEARCH
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240523763
Principal investigator 1 Incyte Corporation $9,965.00 07/17/2025 Non-covered Recipient Entity
DELRICHT RESEARCH
Rollover Study for Participants Previously Enrolled in Clinical Trials of Povorcitinib No dispute reported 06/30/2026 1240523660
Principal investigator 1 Incyte Corporation $1,000.00 07/17/2025 Non-covered Recipient Entity
DELRICHT RESEARCH
Rollover Study for Participants Previously Enrolled in Clinical Trials of Povorcitinib No dispute reported 06/30/2026 1240523668
Principal investigator 1 Incyte Corporation $1,483.00 07/17/2025 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240523672
Principal investigator 1 ABBVIE INC. $5,559.33 07/16/2025 Non-covered Recipient Entity
DELRICHT LLC
BOTOX (onabotulinumtoxinA) for the Reduction of Masseter Muscle Prominence A Phase 3 Multicenter Randomized Double-Blind Placebo-Controlled Study No dispute reported 06/30/2026 1202498402
Principal investigator 1 Incyte Corporation $1,474.00 07/10/2025 Non-covered Recipient Entity
DELRICHT RESEARCH
Rollover Study for Participants Previously Enrolled in Clinical Trials of Povorcitinib No dispute reported 06/30/2026 1240523664
Principal investigator 1 Incyte Corporation $1,385.00 07/10/2025 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240523678
Principal investigator 1 Incyte Corporation $1,553.00 07/09/2025 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240523755
Principal investigator 1 Incyte Corporation $1,553.00 07/09/2025 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240523798
Principal investigator 1 Biofrontera Inc. $300.00 07/02/2025 Non-covered Recipient Entity
DELRICHT RESEARCH
STUDY TO EVALUATE THE SAFETY, TOLERABILITY AND EFFICACY OF BF-200 ALA (AMELUZ) IN THE FIELD-DIRECTED TREATMENT OF ACTINIC KERATOSIS (AK) ON THE EXTREMITIES AND NECK/TRUNK WITH PHOTODYNAMIC THERAPY (PDT) USING A RHODOLED LAMP No dispute reported 06/30/2026 1208907530
Principal investigator 1 Biofrontera Inc. $300.00 07/02/2025 Non-covered Recipient Entity
DELRICHT RESEARCH
STUDY TO EVALUATE THE SAFETY AND EFFICACY OFBF-200ALA(AMELUZ) AND BF-RHODOLED IN THE TREATMENT OF MODERATE TO SEVERE ACNE VULGARIS WITH PHOTODYNAMIC THERAPY IN ADULTS No dispute reported 06/30/2026 1208907534
Principal investigator 1 PFIZER INC. $1,103.49 06/26/2025 Non-covered Recipient Entity
DelRicht LLC
A PHASE 3 RANDOMIZED WITHDRAWAL AND DOSEUP TITRATION MULTICENTER EXTENSION STUDY INVESTIGATING THE SAFETY EFFICACY AND TOLERABILITY OF RITLECITINIB IN ADULT AND ADOLESCENT PARTICIPANTS WITH NONSEGMENTAL VITILIGO No dispute reported 06/30/2026 1228790097
Principal investigator 1 Incyte Corporation $1,599.00 06/25/2025 Non-covered Recipient Entity
DELRICHT RESEARCH
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240523441
Principal investigator 1 Incyte Corporation $4,729.00 06/24/2025 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240523348
Principal investigator 1 Incyte Corporation $30.00 06/23/2025 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240523458
Principal investigator 1 Incyte Corporation $50.00 06/23/2025 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240523587
Principal investigator 1 Incyte Corporation $86.00 06/23/2025 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240523626
Principal investigator 1 ABBVIE INC. $82.00 06/19/2025 Non-covered Recipient Entity
DELRICHT LLC
BOTOX (onabotulinumtoxinA) for the Reduction of Masseter Muscle Prominence A Phase 3 Multicenter Randomized Double-Blind Placebo-Controlled Study No dispute reported 06/30/2026 1202492417
Principal investigator 1 Incyte Corporation $2,537.00 06/19/2025 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240523352
Principal investigator 1 ABBVIE INC. $9,920.19 06/12/2025 Non-covered Recipient Entity
DELRICHT LLC
BOTOX (onabotulinumtoxinA) for the Reduction of Masseter Muscle Prominence A Phase 3 Multicenter Randomized Double-Blind Placebo-Controlled Study No dispute reported 06/30/2026 1202491281
Principal investigator 1 Incyte Corporation $380.00 06/12/2025 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240523346
Principal investigator 1 Incyte Corporation $761.00 06/11/2025 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240523470
Principal investigator 1 Incyte Corporation $100.00 06/11/2025 Non-covered Recipient Entity
DELRICHT RESEARCH
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240523484
Principal investigator 1 SANOFI PASTEUR INC. $1,536.45 06/11/2025 Non-covered Recipient Entity
Delricht Llc
A Phase I/II, Randomized, Placebo-controlled, Multi-arm, Dose-finding Study to Evaluate the Safety, Efficacy and Immunogenicity of an Acne mRNA Vaccine Candidate in Adults With Moderate to Severe Acne 18 to 45 Years of Age No dispute reported 06/30/2026 1226112711
Principal investigator 1 Incyte Corporation $1,553.00 06/06/2025 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240523479
Principal investigator 1 Incyte Corporation $1,553.00 06/06/2025 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240523653
Principal investigator 1 Incyte Corporation $100.00 06/04/2025 Non-covered Recipient Entity
DELRICHT RESEARCH
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240523381
Principal investigator 1 Incyte Corporation $24.72 06/03/2025 Non-covered Recipient Entity
DELRICHT RESEARCH
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240523571
Principal investigator 1 Incyte Corporation $2.72 06/03/2025 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 2, Double-Blind, Randomized, 16-Week, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream Followed by an Open-Label Extension Period in Adults With Chronic Hand Eczema No dispute reported 06/30/2026 1240523577
Principal investigator 1 Incyte Corporation $129.00 06/02/2025 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240523462
Principal investigator 1 Incyte Corporation $40.00 06/02/2025 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240523487
Principal investigator 1 Incyte Corporation $200.00 05/28/2025 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240523331
Principal investigator 1 Incyte Corporation $380.00 05/28/2025 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240523342
Principal investigator 1 SANOFI PASTEUR INC. $18,420.32 05/28/2025 Non-covered Recipient Entity
Delricht Llc
A Phase I/II, Randomized, Placebo-controlled, Multi-arm, Dose-finding Study to Evaluate the Safety, Efficacy and Immunogenicity of an Acne mRNA Vaccine Candidate in Adults With Moderate to Severe Acne 18 to 45 Years of Age No dispute reported 06/30/2026 1226112618
Principal investigator 1 Incyte Corporation $86.00 05/21/2025 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240523390
Principal investigator 1 Incyte Corporation $60.00 05/21/2025 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240523399
Principal investigator 1 Incyte Corporation $1,599.00 05/21/2025 Non-covered Recipient Entity
DELRICHT RESEARCH
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240523407
Principal investigator 1 Incyte Corporation $1,736.00 05/21/2025 Non-covered Recipient Entity
DELRICHT RESEARCH
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240523622
Principal investigator 1 ABBVIE INC. $13,062.00 05/16/2025 Non-covered Recipient Entity
DELRICHT LLC
BOTOX (onabotulinumtoxinA) for the Reduction of Masseter Muscle Prominence A Phase 3 Multicenter Randomized Double-Blind Placebo-Controlled Study No dispute reported 06/30/2026 1202485371
Principal investigator 1 SANOFI PASTEUR INC. $300.00 05/16/2025 Non-covered Recipient Entity
Delricht Llc
A Phase I/II, Randomized, Placebo-controlled, Multi-arm, Dose-finding Study to Evaluate the Safety, Efficacy and Immunogenicity of an Acne mRNA Vaccine Candidate in Adults With Moderate to Severe Acne 18 to 45 Years of Age No dispute reported 06/30/2026 1226112678
Principal investigator 1 Incyte Corporation $380.00 05/15/2025 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240523333
Principal investigator 1 Incyte Corporation $500.00 05/15/2025 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240523337
Principal investigator 1 SANOFI PASTEUR INC. $2,208.80 05/15/2025 Non-covered Recipient Entity
Delricht Llc
A Phase I/II, Randomized, Placebo-controlled, Multi-arm, Dose-finding Study to Evaluate the Safety, Efficacy and Immunogenicity of an Acne mRNA Vaccine Candidate in Adults With Moderate to Severe Acne 18 to 45 Years of Age No dispute reported 06/30/2026 1226112664
Principal investigator 1 PFIZER INC. $50.00 05/14/2025 Non-covered Recipient Entity
DelRicht LLC
A PHASE 3 RANDOMIZED WITHDRAWAL AND DOSEUP TITRATION MULTICENTER EXTENSION STUDY INVESTIGATING THE SAFETY EFFICACY AND TOLERABILITY OF RITLECITINIB IN ADULT AND ADOLESCENT PARTICIPANTS WITH NONSEGMENTAL VITILIGO No dispute reported 06/30/2026 1228783431
Principal investigator 1 SANOFI PASTEUR INC. $4,439.00 05/14/2025 Non-covered Recipient Entity
Delricht Llc
A Phase I/II, Randomized, Placebo-controlled, Multi-arm, Dose-finding Study to Evaluate the Safety, Efficacy and Immunogenicity of an Acne mRNA Vaccine Candidate in Adults With Moderate to Severe Acne 18 to 45 Years of Age No dispute reported 06/30/2026 1226112653
Principal investigator 1 SANOFI PASTEUR INC. $500.00 05/14/2025 Non-covered Recipient Entity
Delricht Llc
A Phase I/II, Randomized, Placebo-controlled, Multi-arm, Dose-finding Study to Evaluate the Safety, Efficacy and Immunogenicity of an Acne mRNA Vaccine Candidate in Adults With Moderate to Severe Acne 18 to 45 Years of Age No dispute reported 06/30/2026 1226112658
Principal investigator 1 SANOFI PASTEUR INC. $14,824.71 05/09/2025 Non-covered Recipient Entity
Delricht Llc
A Phase I/II, Randomized, Placebo-controlled, Multi-arm, Dose-finding Study to Evaluate the Safety, Efficacy and Immunogenicity of an Acne mRNA Vaccine Candidate in Adults With Moderate to Severe Acne 18 to 45 Years of Age No dispute reported 06/30/2026 1226112635
Principal investigator 1 Incyte Corporation $1,696.00 05/08/2025 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240523327
Principal investigator 1 Incyte Corporation $1,553.00 05/07/2025 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240523427
Principal investigator 1 SANOFI PASTEUR INC. $567.58 05/07/2025 Non-covered Recipient Entity
Delricht Llc
A Phase I/II, Randomized, Placebo-controlled, Multi-arm, Dose-finding Study to Evaluate the Safety, Efficacy and Immunogenicity of an Acne mRNA Vaccine Candidate in Adults With Moderate to Severe Acne 18 to 45 Years of Age No dispute reported 06/30/2026 1226112625
Principal investigator 1 Biofrontera Inc. $300.00 05/06/2025 Non-covered Recipient Entity
DELRICHT RESEARCH
STUDY TO EVALUATE THE SAFETY AND EFFICACY OFBF-200ALA(AMELUZ) AND BF-RHODOLED IN THE TREATMENT OF MODERATE TO SEVERE ACNE VULGARIS WITH PHOTODYNAMIC THERAPY IN ADULTS No dispute reported 06/30/2026 1208907445
Principal investigator 1 Biofrontera Inc. $300.00 05/06/2025 Non-covered Recipient Entity
DELRICHT RESEARCH
STUDY TO EVALUATE THE SAFETY, TOLERABILITY AND EFFICACY OF BF-200 ALA (AMELUZ) IN THE FIELD-DIRECTED TREATMENT OF ACTINIC KERATOSIS (AK) ON THE EXTREMITIES AND NECK/TRUNK WITH PHOTODYNAMIC THERAPY (PDT) USING A RHODOLED LAMP No dispute reported 06/30/2026 1208907449
Principal investigator 1 PFIZER INC. $3,502.89 05/06/2025 Non-covered Recipient Entity
DelRicht LLC
A PHASE 3 RANDOMIZED WITHDRAWAL AND DOSEUP TITRATION MULTICENTER EXTENSION STUDY INVESTIGATING THE SAFETY EFFICACY AND TOLERABILITY OF RITLECITINIB IN ADULT AND ADOLESCENT PARTICIPANTS WITH NONSEGMENTAL VITILIGO No dispute reported 06/30/2026 1228772022
Principal investigator 1 Incyte Corporation $300.00 05/02/2025 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240523355
Principal investigator 1 Incyte Corporation $50.00 05/02/2025 Non-covered Recipient Entity
DELRICHT RESEARCH
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240523361
Principal investigator 1 Incyte Corporation $113.26 05/02/2025 Non-covered Recipient Entity
DELRICHT RESEARCH
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240523366
Principal investigator 1 Incyte Corporation $100.00 05/02/2025 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240523416
Principal investigator 1 Incyte Corporation $816.00 05/02/2025 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240523420
Principal investigator 1 Incyte Corporation $258.00 05/02/2025 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240523423
Principal investigator 1 Incyte Corporation $300.00 05/02/2025 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240523431
Principal investigator 1 Incyte Corporation $43.00 05/02/2025 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240523434
Principal investigator 1 Incyte Corporation $100.00 05/02/2025 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240523438
Principal investigator 1 Incyte Corporation $1,599.00 05/02/2025 Non-covered Recipient Entity
DELRICHT RESEARCH
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240523446
Principal investigator 1 Incyte Corporation $30.00 05/02/2025 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240523449
Principal investigator 1 Incyte Corporation $86.00 05/02/2025 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240523454
Principal investigator 1 Incyte Corporation $14.84 05/02/2025 Non-covered Recipient Entity
DELRICHT RESEARCH
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240523558
Principal investigator 1 Incyte Corporation $74.04 05/02/2025 Non-covered Recipient Entity
DELRICHT RESEARCH
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240523567
Principal investigator 1 Incyte Corporation $190.00 05/02/2025 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240523582
Principal investigator 1 Incyte Corporation $57.54 05/02/2025 Non-covered Recipient Entity
DELRICHT RESEARCH
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240523605
Principal investigator 1 Incyte Corporation $57.54 05/02/2025 Non-covered Recipient Entity
DELRICHT RESEARCH
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240523609
Principal investigator 1 Incyte Corporation $57.54 05/02/2025 Non-covered Recipient Entity
DELRICHT RESEARCH
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240523614
Principal investigator 1 Incyte Corporation $57.54 05/02/2025 Non-covered Recipient Entity
DELRICHT RESEARCH
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240523618
Principal investigator 1 Incyte Corporation $100.00 05/02/2025 Non-covered Recipient Entity
DELRICHT RESEARCH
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240523637
Principal investigator 1 Incyte Corporation $380.00 04/28/2025 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240523308
Principal investigator 1 ABBVIE INC. $126.00 04/23/2025 Non-covered Recipient Entity
DELRICHT LLC
BOTOX (onabotulinumtoxinA) for the Reduction of Masseter Muscle Prominence A Phase 3 Multicenter Randomized Double-Blind Placebo-Controlled Study No dispute reported 06/30/2026 1202478671
Principal investigator 1 Eli Lilly and Company $2,015.46 04/23/2025 Non-covered Recipient Entity
DELRICHT LLC
EFFICACY AND SAFETY OF IXEKIZUMAB OR IXEKIZUMAB CONCOMITANTLY ADMINISTERED WITH TIRZEPATIDE IN ADULT PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS AND OBESITY OR OVERWEIGHT: A PHASE 3B, RANDOMIZED, MULTICENTER, OPEN-LABEL STUDY (TOGETHER-PSO) No dispute reported 06/30/2026 1187878719
Principal investigator 1 Incyte Corporation $50.00 04/23/2025 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240523320
Principal investigator 1 Incyte Corporation $200.00 04/18/2025 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240523370
Principal investigator 1 Incyte Corporation $30.00 04/18/2025 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240523374
Principal investigator 1 Incyte Corporation $129.00 04/18/2025 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240523377
Principal investigator 1 Biofrontera Inc. $24.59 04/17/2025 Non-covered Recipient Entity
DELRICHT RESEARCH
STUDY TO EVALUATE THE SAFETY, TOLERABILITY AND EFFICACY OF BF-200 ALA (AMELUZ) IN THE FIELD-DIRECTED TREATMENT OF ACTINIC KERATOSIS (AK) ON THE EXTREMITIES AND NECK/TRUNK WITH PHOTODYNAMIC THERAPY (PDT) USING A RHODOLED LAMP No dispute reported 06/30/2026 1208907441
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $7,764.00 04/17/2025 Non-covered Recipient Entity
Delricht Llc
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Effect of Deucravacitinib on Quality of Life in Participants With Plaque Psoriasis in a Community Setting No dispute reported 06/30/2026 1235997738
Principal investigator 1 ABBVIE INC. $11,429.25 04/16/2025 Non-covered Recipient Entity
DELRICHT LLC
BOTOX (onabotulinumtoxinA) for the Reduction of Masseter Muscle Prominence A Phase 3 Multicenter Randomized Double-Blind Placebo-Controlled Study No dispute reported 06/30/2026 1202476986
Principal investigator 1 Incyte Corporation $3,947.00 04/15/2025 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240523312
Principal investigator 1 PFIZER INC. $2,891.09 04/10/2025 Non-covered Recipient Entity
DelRicht LLC
A PHASE 3 RANDOMIZED WITHDRAWAL AND DOSEUP TITRATION MULTICENTER EXTENSION STUDY INVESTIGATING THE SAFETY EFFICACY AND TOLERABILITY OF RITLECITINIB IN ADULT AND ADOLESCENT PARTICIPANTS WITH NONSEGMENTAL VITILIGO No dispute reported 06/30/2026 1228780768
Principal investigator 1 Incyte Corporation $500.00 04/09/2025 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240523563
Principal investigator 1 Incyte Corporation $3,748.00 04/08/2025 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240523323
Principal investigator 1 Incyte Corporation $1,553.00 04/07/2025 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240523386
Principal investigator 1 Incyte Corporation $1,597.00 04/07/2025 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240523402
Principal investigator 1 Biofrontera Inc. $300.00 04/03/2025 Non-covered Recipient Entity
DELRICHT RESEARCH
STUDY TO EVALUATE THE SAFETY AND EFFICACY OFBF-200ALA(AMELUZ) AND BF-RHODOLED IN THE TREATMENT OF MODERATE TO SEVERE ACNE VULGARIS WITH PHOTODYNAMIC THERAPY IN ADULTS No dispute reported 06/30/2026 1208907390
Principal investigator 1 Biofrontera Inc. $300.00 04/03/2025 Non-covered Recipient Entity
DELRICHT RESEARCH
STUDY TO EVALUATE THE SAFETY, TOLERABILITY AND EFFICACY OF BF-200 ALA (AMELUZ) IN THE FIELD-DIRECTED TREATMENT OF ACTINIC KERATOSIS (AK) ON THE EXTREMITIES AND NECK/TRUNK WITH PHOTODYNAMIC THERAPY (PDT) USING A RHODOLED LAMP No dispute reported 06/30/2026 1208907395
Principal investigator 1 Incyte Corporation $1,736.00 04/02/2025 Non-covered Recipient Entity
DELRICHT RESEARCH
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240523394
Principal investigator 1 Incyte Corporation $1,599.00 04/02/2025 Non-covered Recipient Entity
DELRICHT RESEARCH
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240523411
Principal investigator 1 Incyte Corporation $48.54 04/02/2025 Non-covered Recipient Entity
DELRICHT RESEARCH
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240523466
Principal investigator 1 Incyte Corporation $148.85 04/02/2025 Non-covered Recipient Entity
DELRICHT RESEARCH
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240523475
Principal investigator 1 Incyte Corporation $143.10 04/02/2025 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240523491
Principal investigator 1 Incyte Corporation $63.60 04/02/2025 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240523495
Principal investigator 1 Incyte Corporation $74.20 04/02/2025 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240523499
Principal investigator 1 Incyte Corporation $249.08 04/02/2025 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240523503
Principal investigator 1 Incyte Corporation $295.65 04/02/2025 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240523506
Principal investigator 1 Incyte Corporation $114.50 04/02/2025 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240523511
Principal investigator 1 Incyte Corporation $21.87 04/02/2025 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240523515
Principal investigator 1 Incyte Corporation $74.04 04/02/2025 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240523519
Principal investigator 1 Incyte Corporation $80.90 04/02/2025 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240523524
Principal investigator 1 Incyte Corporation $33.99 04/02/2025 Non-covered Recipient Entity
DELRICHT RESEARCH
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240523528
Principal investigator 1 Incyte Corporation $541.60 04/02/2025 Non-covered Recipient Entity
DELRICHT RESEARCH
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240523530
Principal investigator 1 Incyte Corporation $16.14 04/02/2025 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240523534
Principal investigator 1 Incyte Corporation $236.52 04/02/2025 Non-covered Recipient Entity
DELRICHT RESEARCH
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240523538
Principal investigator 1 Incyte Corporation $37.66 04/02/2025 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240523542
Principal investigator 1 Incyte Corporation $10.76 04/02/2025 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240523545
Principal investigator 1 Incyte Corporation $328.60 04/02/2025 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240523550
Principal investigator 1 Incyte Corporation $32.28 04/02/2025 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240523554
Principal investigator 1 Incyte Corporation $24.66 04/02/2025 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240523591
Principal investigator 1 Incyte Corporation $24.66 04/02/2025 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240523594
Principal investigator 1 Incyte Corporation $24.66 04/02/2025 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240523597
Principal investigator 1 Incyte Corporation $24.66 04/02/2025 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240523600
Principal investigator 1 Incyte Corporation $48.42 04/02/2025 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240523631
Principal investigator 1 Incyte Corporation $254.40 04/02/2025 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240523640
Principal investigator 1 Incyte Corporation $10.76 04/02/2025 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240523646
Principal investigator 1 Incyte Corporation $1.55 04/02/2025 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240523649
Principal investigator 1 Incyte Corporation $5,611.00 04/01/2025 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240523317
Principal investigator 1 SANOFI PASTEUR INC. $11,928.92 03/21/2025 Non-covered Recipient Entity
Delricht Llc
A Phase I/II, Randomized, Placebo-controlled, Multi-arm, Dose-finding Study to Evaluate the Safety, Efficacy and Immunogenicity of an Acne mRNA Vaccine Candidate in Adults With Moderate to Severe Acne 18 to 45 Years of Age No dispute reported 06/30/2026 1226112583
Principal investigator 1 ABBVIE INC. $630.00 03/20/2025 Non-covered Recipient Entity
DELRICHT LLC
M21-417 - BOTOX (onabotulinumtoxinA) for the Reduction of Masseter Muscle Prominence A Phase 3 Multicenter Randomized Double-Blind Placebo-Controlled Study No dispute reported 06/30/2026 1202465023
Principal investigator 1 SANOFI PASTEUR INC. $300.00 03/18/2025 Non-covered Recipient Entity
Delricht Llc
A Phase I/II, Randomized, Placebo-controlled, Multi-arm, Dose-finding Study to Evaluate the Safety, Efficacy and Immunogenicity of an Acne mRNA Vaccine Candidate in Adults With Moderate to Severe Acne 18 to 45 Years of Age No dispute reported 06/30/2026 1226112566
Principal investigator 1 PFIZER INC. $2,891.09 03/14/2025 Non-covered Recipient Entity
DelRicht LLC
A PHASE 3 RANDOMIZED WITHDRAWAL AND DOSEUP TITRATION MULTICENTER EXTENSION STUDY INVESTIGATING THE SAFETY EFFICACY AND TOLERABILITY OF RITLECITINIB IN ADULT AND ADOLESCENT PARTICIPANTS WITH NONSEGMENTAL VITILIGO No dispute reported 06/30/2026 1228781479
Principal investigator 1 ABBVIE INC. $11,429.25 03/13/2025 Non-covered Recipient Entity
DELRICHT LLC
M21-417 - BOTOX (onabotulinumtoxinA) for the Reduction of Masseter Muscle Prominence A Phase 3 Multicenter Randomized Double-Blind Placebo-Controlled Study No dispute reported 06/30/2026 1202463186
Principal investigator 1 ABBVIE INC. $752.00 03/12/2025 Non-covered Recipient Entity
DELRICHT LLC
M21-417 - BOTOX (onabotulinumtoxinA) for the Reduction of Masseter Muscle Prominence A Phase 3 Multicenter Randomized Double-Blind Placebo-Controlled Study No dispute reported 06/30/2026 1202462664
Principal investigator 1 Incyte Corporation $1,718.00 03/12/2025 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240523282
Principal investigator 1 Incyte Corporation $1,553.00 03/12/2025 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240523289
Principal investigator 1 Incyte Corporation $1,385.00 03/11/2025 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240523234
Principal investigator 1 Incyte Corporation $3,369.00 03/04/2025 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240523229
Principal investigator 1 Incyte Corporation $1,740.00 03/03/2025 Non-covered Recipient Entity
DELRICHT RESEARCH
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240523285
Principal investigator 1 Incyte Corporation $446.00 03/03/2025 Non-covered Recipient Entity
DELRICHT RESEARCH
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240523300
Principal investigator 1 Biofrontera Inc. $4,153.81 02/28/2025 Non-covered Recipient Entity
DELRICHT RESEARCH
STUDY TO EVALUATE THE SAFETY AND EFFICACY OFBF-200ALA(AMELUZ) AND BF-RHODOLED IN THE TREATMENT OF MODERATE TO SEVERE ACNE VULGARIS WITH PHOTODYNAMIC THERAPY IN ADULTS No dispute reported 06/30/2026 1208907354
Principal investigator 1 Biofrontera Inc. $10,500.00 02/28/2025 Non-covered Recipient Entity
DELRICHT RESEARCH
STUDY TO EVALUATE THE SAFETY, TOLERABILITY AND EFFICACY OF BF-200 ALA (AMELUZ) IN THE FIELD-DIRECTED TREATMENT OF ACTINIC KERATOSIS (AK) ON THE EXTREMITIES AND NECK/TRUNK WITH PHOTODYNAMIC THERAPY (PDT) USING A RHODOLED LAMP No dispute reported 06/30/2026 1208907359
Principal investigator 1 Biofrontera Inc. $500.00 02/28/2025 Non-covered Recipient Entity
DELRICHT RESEARCH
STUDY TO EVALUATE THE SAFETY AND EFFICACY OFBF-200ALA(AMELUZ) AND BF-RHODOLED IN THE TREATMENT OF MODERATE TO SEVERE ACNE VULGARIS WITH PHOTODYNAMIC THERAPY IN ADULTS No dispute reported 06/30/2026 1208907363
Principal investigator 1 Incyte Corporation $9,007.00 02/25/2025 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240524246
Principal investigator 1 Incyte Corporation $1,718.00 02/19/2025 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240523265
Principal investigator 1 Incyte Corporation $2,200.00 02/19/2025 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240523297
Principal investigator 1 Incyte Corporation $2,200.00 02/19/2025 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240523304
Principal investigator 1 SANOFI PASTEUR INC. $23,707.52 02/17/2025 Non-covered Recipient Entity
Delricht Llc
A Phase I/II, Randomized, Placebo-controlled, Multi-arm, Dose-finding Study to Evaluate the Safety, Efficacy and Immunogenicity of an Acne mRNA Vaccine Candidate in Adults With Moderate to Severe Acne 18 to 45 Years of Age No dispute reported 06/30/2026 1226112547
Principal investigator 1 Biofrontera Inc. $300.00 02/14/2025 Non-covered Recipient Entity
DELRICHT RESEARCH
STUDY TO EVALUATE THE SAFETY AND EFFICACY OFBF-200ALA(AMELUZ) AND BF-RHODOLED IN THE TREATMENT OF MODERATE TO SEVERE ACNE VULGARIS WITH PHOTODYNAMIC THERAPY IN ADULTS No dispute reported 06/30/2026 1208907305
Principal investigator 1 ABBVIE INC. $13,152.44 02/13/2025 Non-covered Recipient Entity
DELRICHT LLC
M21-417 - BOTOX (onabotulinumtoxinA) for the Reduction of Masseter Muscle Prominence A Phase 3 Multicenter Randomized Double-Blind Placebo-Controlled Study No dispute reported 06/30/2026 1202451497
Principal investigator 1 Eli Lilly and Company $74,857.69 02/10/2025 Non-covered Recipient Entity
DELRICHT LLC
EFFICACY AND SAFETY OF IXEKIZUMAB OR IXEKIZUMAB CONCOMITANTLY ADMINISTERED WITH TIRZEPATIDE IN ADULT PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS AND OBESITY OR OVERWEIGHT: A PHASE 3B, RANDOMIZED, MULTICENTER, OPEN-LABEL STUDY (TOGETHER-PSO) No dispute reported 06/30/2026 1187879723
Principal investigator 1 Incyte Corporation $300.00 02/07/2025 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240523293
Principal investigator 1 PFIZER INC. $724.44 02/06/2025 Non-covered Recipient Entity
DelRicht LLC
A PHASE 3 RANDOMIZED WITHDRAWAL AND DOSEUP TITRATION MULTICENTER EXTENSION STUDY INVESTIGATING THE SAFETY EFFICACY AND TOLERABILITY OF RITLECITINIB IN ADULT AND ADOLESCENT PARTICIPANTS WITH NONSEGMENTAL VITILIGO No dispute reported 06/30/2026 1228770008
Principal investigator 1 Biofrontera Inc. $23.99 01/30/2025 Non-covered Recipient Entity
DELRICHT RESEARCH
STUDY TO EVALUATE THE SAFETY, TOLERABILITY AND EFFICACY OF BF-200 ALA (AMELUZ) IN THE FIELD-DIRECTED TREATMENT OF ACTINIC KERATOSIS (AK) ON THE EXTREMITIES AND NECK/TRUNK WITH PHOTODYNAMIC THERAPY (PDT) USING A RHODOLED LAMP No dispute reported 06/30/2026 1208907275
Principal investigator 1 Incyte Corporation $2,802.00 01/29/2025 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240524234
Principal investigator 1 Incyte Corporation $2,524.00 01/27/2025 Non-covered Recipient Entity
DELRICHT RESEARCH
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240523242
Principal investigator 1 Incyte Corporation $2,377.00 01/27/2025 Non-covered Recipient Entity
DELRICHT RESEARCH
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240523252
Principal investigator 1 Incyte Corporation $300.00 01/24/2025 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 2, Double-Blind, Randomized, 16-Week, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream Followed by an Open-Label Extension Period in Adults With Chronic Hand Eczema No dispute reported 06/30/2026 1240523269
Principal investigator 1 PFIZER INC. $2,131.66 01/24/2025 Non-covered Recipient Entity
DelRicht LLC
A PHASE 3 RANDOMIZED WITHDRAWAL AND DOSEUP TITRATION MULTICENTER EXTENSION STUDY INVESTIGATING THE SAFETY EFFICACY AND TOLERABILITY OF RITLECITINIB IN ADULT AND ADOLESCENT PARTICIPANTS WITH NONSEGMENTAL VITILIGO No dispute reported 06/30/2026 1228801276
Principal investigator 1 Incyte Corporation $2,500.00 01/23/2025 Non-covered Recipient Entity
LOUISIANA DERMATOLOGY ASSOCIATES
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream Followed by a Long-Term Safety Extension Period in Children (Ages 2 Years to 12 Years) With Atopic Dermatitis (TRuE-AD3) No dispute reported 06/30/2026 1240547963
Principal investigator 1 ABBVIE INC. $2,041.00 01/22/2025 Non-covered Recipient Entity
DELRICHT LLC
M21-417 - BOTOX (onabotulinumtoxinA) for the Reduction of Masseter Muscle Prominence A Phase 3 Multicenter Randomized Double-Blind Placebo-Controlled Study No dispute reported 06/30/2026 1202440581
Principal investigator 1 Incyte Corporation $4,643.00 01/21/2025 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240524238
Principal investigator 1 Incyte Corporation $1,553.00 01/17/2025 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240523256
Principal investigator 1 Incyte Corporation $1,684.00 01/17/2025 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240523260
Principal investigator 1 Incyte Corporation $1,664.00 01/17/2025 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240523274
Principal investigator 1 Incyte Corporation $1,664.00 01/17/2025 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240523278
Principal investigator 1 Incyte Corporation $300.00 01/17/2025 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240524241
Principal investigator 1 Incyte Corporation $11,130.00 01/17/2025 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240524243
Principal investigator 1 ABBVIE INC. $15,146.95 01/16/2025 Non-covered Recipient Entity
DELRICHT LLC
M21-417 - BOTOX (onabotulinumtoxinA) for the Reduction of Masseter Muscle Prominence A Phase 3 Multicenter Randomized Double-Blind Placebo-Controlled Study No dispute reported 06/30/2026 1202439483
Principal investigator 1 Incyte Corporation $2,377.00 01/15/2025 Non-covered Recipient Entity
DELRICHT RESEARCH
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240523238
Principal investigator 1 SANOFI PASTEUR INC. $300.00 01/09/2025 Non-covered Recipient Entity
Delricht Llc
A Phase I/II, Randomized, Placebo-controlled, Multi-arm, Dose-finding Study to Evaluate the Safety, Efficacy and Immunogenicity of an Acne mRNA Vaccine Candidate in Adults With Moderate to Severe Acne 18 to 45 Years of Age No dispute reported 06/30/2026 1226112541
Principal investigator 1 Incyte Corporation $300.00 01/08/2025 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240523247